D-0629-2020 Class III Terminated
FDA drug recall D-0629-2020 was initiated by Lupin Pharmaceuticals Inc. on Dec 10, 2019 and is designated Class III. Reason for recall: Failed Dissolution Specifications: High out of specification result observed at stability studies. The recall status is terminated (terminated Apr 29, 2021). Affected quantity: 3,726 bottles.
Recall details
- Product Type
- Drugs
- Report Date
- Dec 25, 2019
- Initiation Date
- Dec 10, 2019
- Termination Date
- Apr 29, 2021
- Voluntary/Mandated
- Voluntary: Firm initiated
- Product Quantity
- 3,726 bottles
Product description
Memantine Hydrochloride Extended-release Capsules, 28mg, packaged in a) 90-count bottles (NDC 68180-249-09 and b) 500-count bottles (NDC 68180-249-02); Rx only, Manufactured for: Lupin Pharmaceuticals, Inc., Baltimore, Maryland 21202; Manufactured by: Lupin Limited, Pithampur (M.P.)-454 775, INDIA
Reason for recall
Failed Dissolution Specifications: High out of specification result observed at stability studies.
Distribution pattern
Nationwide in the USA
Code information
Lot #: H901787, H901788, Exp March 2021
Source
- Dataset
- openFDA drug recall enforcement reports
- FDA record
- This recall in openFDA (JSON)
- Enforcement Report
- Search FDA's Enforcement Report for D-0629-2020
- openFDA file date
- Nov 10, 2026
- Loaded by RegDataLab
- Nov 11, 2026